BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Zymeworks (ZYME) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts ↗

December 03, 2024

Via Benzinga

Why Is BeiGene Stock Trading Higher On Wednesday? ↗

November 27, 2024

BeiGene's Tevimbra receives EU approval for advanced ESCC and G/GEJ cancers, showing significant survival benefits in pivotal Phase 3 trials.

Via Benzinga

Expert Outlook: BeiGene Through The Eyes Of 4 Analysts ↗

October 22, 2024

Via Benzinga

What Analysts Are Saying About BeiGene Stock ↗

September 18, 2024

Via Benzinga

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Why Summit Therapeutics Rocketed Double-Digits Today ↗

April 23, 2025

Via The Motley Fool

Topics World Trade

Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio? ↗

December 15, 2024

Large-cap stocks saw worst performance last week, including MongoDB, Applovin, CAVA, Super Micro Computer, FTAI, Adobe, Ferguson, Toll Brothers, BeiGene, Omnicom, and Nucor.

Via Benzinga

Top 2 Health Care Stocks That May Plunge In August ↗

August 26, 2024

Via Benzinga

Evaluating BeiGene: Insights From 6 Financial Analysts ↗

April 24, 2024

Via Benzinga

US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio? ↗

October 06, 2024

Best performing large-cap stocks in the past week were mostly USA listed Chinese stocks due to additional stimulus measures to boost China's economy.

Via Benzinga

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗

September 25, 2024

The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.

Via Benzinga

Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug ↗

September 18, 2024

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the...

Via Benzinga

Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 12, 2024

Via Benzinga

Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗

September 12, 2024

Via Benzinga

Innovent Bio hopes for plus-sized profits from obesity drug ↗

September 06, 2024

Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival products to gain a market advantage The executive in charge of...

Via Benzinga

Topics Retirement

Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million ↗

August 31, 2024

UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and...

Via Talk Markets

Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer ↗

August 23, 2024

The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and...

Via Benzinga

Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal ↗

July 27, 2024

Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...

Via Talk Markets

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? ↗

July 22, 2024

The big pharma company's top drug is losing ground, but its dividend keeps rising.

Via The Motley Fool

Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio? ↗

June 30, 2024

10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com, Ecopetrol, International Paper, Micron.

Via Benzinga

What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? ↗

June 17, 2024

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for...

Via Benzinga

Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare ↗

June 15, 2024

Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...

Via Talk Markets

7 Large-Cap Stocks That Can Jump 50% By 2025 ↗

May 29, 2024

It isn't easy to find large-cap stocks offering 50% upside but that's exactly what this list provides for investors.

Via InvestorPlace

Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio? ↗

May 26, 2024

10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululemon, Walgreens, and Li Auto.

Via Benzinga

Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings ↗

May 25, 2024

Via Talk Markets

BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

BGNE stock results show that BeiGene beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024) ↗

April 28, 2024

Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation.

Via Benzinga

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday ↗

April 23, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.